<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055025</url>
  </required_header>
  <id_info>
    <org_study_id>H-19010763</org_study_id>
    <nct_id>NCT04055025</nct_id>
  </id_info>
  <brief_title>Physiological Responses to Laparoscopic Sleeve Gastrectomy: Focusing on Ghrelin</brief_title>
  <official_title>Physiological Responses to Laparoscopic Sleeve Gastrectomy: Focusing on Ghrelin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that decreased concentration of ghrelin after LSG is important for the
      decreased appetite and food intake postoperatively. We therefore expect infusion of ghrelin
      will increase an ad libitum food intake after LSG. We also expect that a decreased
      postprandial concentration of ghrelin after LSG play a role for increased insulin secretion
      and decreased postprandial plasma glucose concentrations after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) are
      to bariatric procedure. After both procedures, a changed secretion of hormones from the
      gastrointestinal tract is believed to affect appetite and glucose metabolism. Studies have
      shown that after LRYGB, there is a significant increased secretion of GLP-1 and PYY. In
      contrast, a decreased secretion of ghrelin is a characteristic finding after LSG opposite
      post-LRYGB, where secretion of ghrelin is reported to be increased, decreased or unchanged.
      Ghrelin is primarily secreted from the gastric mucosa in the fasting state and decreases in
      response to food intake. Ghrelin stimulates food intake through appetite-regulating centers
      in the hypothalamus. Administration of exogenous ghrelin has been reported to stimulate
      appetite. In addition, ghrelin has recently been suggested also to affect glucose metabolism
      by inhibition of glucose-stimulated insulin secretion. Therefore the markedly decreased
      secretion of ghrelin could be of particular important for the decreased appetite and improved
      glucose tolerance seen after LSG.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The study visits will be performed in randomized orders and participants will not now if they will receive ghrelin or saline.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ad libitum</measure>
    <time_frame>240 minutes</time_frame>
    <description>Ad libitum food intake (gram) with and without infusion of ghrelin at 3 months after LSG surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ad libitum</measure>
    <time_frame>240 minutes</time_frame>
    <description>Ad libitum food intake (gram) with and without ghrelin infusion before surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>240 minutes</time_frame>
    <description>Plasma concentration profile of ghrelin (AUC) before and after LSG.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>Sleeve gastrectomy operated patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Five test days in a randomized, patient-blinded, cross-over design</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.</description>
    <arm_group_label>Sleeve gastrectomy operated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ghrelin</intervention_name>
    <description>Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.</description>
    <arm_group_label>Sleeve gastrectomy operated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The Danish national inclusion criteria for bariatric surgery

          -  Signed written informed consent

          -  Fasting plasma glucose &lt;6.1 mmol/l

        Exclusion Criteria:

          -  Pregnancy or breastfeeding.

          -  Hemoglobin &lt;6.5 mM

          -  Newly emerged serious disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora Hedb채ck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, Hvidovre University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nora Hedb채ck, MD</last_name>
    <phone>+4538620340</phone>
    <email>nora.elisabeth.hedbaeck.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria S Svane, MD, PHD</last_name>
    <phone>+4538620340</phone>
    <email>maria.saur.svane@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology, Hvidovre University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Hvidovre</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora Hedb채ck, MD</last_name>
      <phone>+4538620340</phone>
      <email>nora.elisabeth.hedbaeck.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Maria S Svane, MD, PHD</last_name>
      <phone>+4538620340</phone>
      <email>maria.saur.svane@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Nora Elisabeth Hedb채ck</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Ghrelin</keyword>
  <keyword>Sleeve gastrectomy</keyword>
  <keyword>Laparoscopic sleeve gastrectomy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

